期刊
JOURNAL OF PHARMACEUTICAL ANALYSIS
卷 13, 期 2, 页码 127-141出版社
ELSEVIER
DOI: 10.1016/j.jpha.2022.11.009
关键词
Cancer; Epigenetics; Histone lysine methyltransferase; Epigenetic inhibitors; Combined therapeutic strategy; Clinical application
The reversible and precise regulation of histone lysine methyltransferases (KMTs) is crucial for maintaining the stability of the epigenome. Dysregulation of KMTs is associated with various aspects of cancer progression and response to treatment. In this review, the functions of KMTs and the development of targeted inhibitors are discussed, along with current targeting strategies and ongoing clinical trials.
The reversible and precise temporal and spatial regulation of histone lysine methyltransferases (KMTs) is essential for epigenome homeostasis. The dysregulation of KMTs is associated with tumor initiation, metastasis, chemoresistance, invasiveness, and the immune microenvironment. Therapeutically, their promising effects are being evaluated in diversified preclinical and clinical trials, demonstrating encouraging outcomes in multiple malignancies. In this review, we have updated recent understandings of KMTs' functions and the development of their targeted inhibitors. First, we provide an updated overview of the regulatory roles of several KMT activities in oncogenesis, tumor suppression, and im-mune regulation. In addition, we summarize the current targeting strategies in different cancer types and multiple ongoing clinical trials of combination therapies with KMT inhibitors. In summary, we endeavor to depict the regulation of KMT-mediated epigenetic landscape and provide potential epigenetic targets in the treatment of cancers.(c) 2022 Published by Elsevier B.V. on behalf of Xi'an Jiaotong University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据